By Editorial Team
Neko HealthIndependently confirmed
Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.
The round
Neko Health, a digital health company specializing in health assessments, has successfully raised $700 million in a Series C funding round. The investment was co-led by Lightspeed Venture Partners and O.G. Venture Partners. Other participants in the round included Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT MSD. This significant capital infusion follows a previous $260 million Series B round for the company in January 2025.
What Neko Health does
Neko Health has developed proprietary body-scanning technology that it integrates with bloodwork to provide comprehensive health assessments. The company’s offerings now also include body composition information, a feature that may appeal to individuals focused on fitness. Neko Health’s system can also incorporate data from Apple Health, which its medical clinicians utilize to enhance their assessments with real-world health information. The company was co-founded by Spotify’s Daniel Ek and Hjalmar Nilsonne. Neko Health currently operates in the U.K. and Sweden and is preparing to open its first U.S. location in New York. The company reports that over 100,000 individuals have already undergone its scans, and more than 350,000 people have either joined a waitlist or scheduled an appointment. An example of the impact of Neko Health’s assessments was shared by Calm founder Alex Tew, who reported on X that a scan identified a malignant mole on his back, which he subsequently had removed.
What the funding will do
The intended use of the recently secured $700 million was not disclosed in the provided information.
Why it matters
This substantial funding round highlights continued investor interest in the digital health sector, particularly in companies offering advanced diagnostic and preventative health solutions. Neko Health’s approach, combining proprietary body-scanning technology with bloodwork and integrating real-world health data, positions it within a growing segment focused on proactive health management. The company’s expansion into the U.S. market, following its established presence in Europe, signals a broader ambition to make its health assessment technology accessible to a wider population. The reported traction, with a significant number of scans performed and a large waitlist, suggests a demand for such comprehensive health insights.